The purpose of this research is to verify if TAR-0520 Gel is safe when applied to the skin of one hand and one foot twice daily. The gel belongs to a group of medications called alpha 2 agonists, which are substances that can affect nerve signals. During the study, participants will apply the gel for up to 36 weeks while receiving their regular cancer treatment.

The study will monitor how patients’ bodies react to the gel, both at the application site and throughout the body. Healthcare providers will regularly check for any side effects and evaluate if there are any changes in nerve-related symptoms. This research will help determine if the gel could be a useful treatment option for preventing nerve damage in cancer patients.

Participants in the study will receive either psilocybin capsules or a placebo. The psilocybin capsules come in two different doses: 1 mg and 25 mg. The study aims to see if psilocybin can help reduce the interference of pain with daily activities. The trial will also look at how participants feel about the treatment and any changes in their emotional and psychological well-being. The study will be conducted over a short period, with participants taking the medication orally.

The main goal of the study is to assess how feasible it is to use psilocybin as a treatment for chronic neuropathic pain caused by chemotherapy. Researchers will also gather information on how well participants tolerate the treatment and any side effects they might experience. This trial is an important step in understanding whether psilocybin could be a helpful option for managing pain in people who have undergone chemotherapy.

The study will be conducted in two parts over a period of 24 months. Participants will receive either the AT-007 treatment or a placebo, which is a substance with no active medication. The study will monitor changes in the levels of sorbitol, a type of sugar, in the blood over 12 months. Additionally, the study will assess the impact of the treatment on participants’ ability to walk or run a short distance over 24 months. This will help determine if AT-007 can improve physical function in people with SORD Deficiency.

Throughout the study, participants will undergo various assessments, including the 10-meter walk/run test (10MWRT), to measure their physical abilities. The study will also look at changes in muscle composition using MRI scans and gather feedback from participants about how the disease and treatment affect their daily lives. The goal is to understand the potential benefits of AT-007 for individuals with SORD Deficiency and to gather valuable information that could lead to improved treatment options in the future.

Participants in the study will receive either the ozone therapy or a placebo, which is a substance with no active therapeutic effect. The study is designed to be triple-blind, meaning that neither the participants, the healthcare providers, nor the researchers know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The treatment will be administered rectally, which means it is given through the rectum. The study will last for a period of time, during which participants will be monitored for changes in their pain levels and overall health.

The main goal is to assess how the addition of ozone therapy affects pain and self-perceived health-related quality of life. The study will also look at the cost-effectiveness of this treatment, meaning it will evaluate whether the benefits of the therapy justify the costs involved. Participants’ quality of life will be measured using questionnaires, and other factors like anxiety, depression, and nerve function will also be assessed. The study aims to provide valuable information on whether ozone therapy can be a beneficial addition to the standard management of pain in patients with chemotherapy-induced peripheral neuropathy.

The treatment involves using a mixture of ozone and oxygen, which is administered through a method called rectal insufflation. This means the gas mixture is introduced into the body through the rectum. The study aims to determine if adding ozone to the usual care for paresthesia can help patients feel better and improve their daily lives. The trial will also look at how this treatment affects patients’ overall health and well-being over a period of time.

Participants in the study will receive the treatment over a period of 16 weeks, with follow-up assessments continuing for up to 28 weeks. The study will measure changes in the level of numbness and tingling that patients feel, as well as their overall quality of life. The goal is to find out if this new approach can offer a beneficial addition to the current management of paresthesia caused by chemotherapy.

The main goal of the study is to investigate whether Botox can provide pain relief for individuals suffering from chronic neuropathic pain. Participants in the study will receive either the Botox injection or a placebo. The study will monitor the participants over a period of time to assess changes in their pain levels and overall satisfaction with the treatment. The study will also look at how quickly the pain relief begins and how long it lasts.

Throughout the study, participants will be asked to report on their pain levels, any changes in their daily activities, and their overall satisfaction with the treatment. The study aims to provide valuable information on the potential benefits of using Botox for managing chronic neuropathic pain, which could lead to improved treatment options for those affected by this condition.

Participants in the study will be divided into two groups. One group will receive the AP707 treatment, while the other group will receive a placebo, which looks and smells like the real treatment but does not contain the active ingredient. The study will last for about a year, during which participants will have regular check-ups to monitor their pain levels and overall health. The goal is to determine if AP707 can effectively reduce pain and improve the quality of life for those suffering from chronic pain due to nerve damage.

Throughout the study, participants will continue to use their regular pain medications, which may include drugs like Gabapentin, Capsaicin, Imipramine, Amitriptyline, and Paracetamol. These medications are commonly used to manage pain and will be optimized for each participant. The study will also assess any changes in psychological well-being, sleep quality, and overall life satisfaction. By the end of the study, researchers hope to gather valuable information on the potential benefits of AP707 for managing chronic pain.

Participants in the study will receive either the AP707 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for a total of 52 weeks, during which participants will be monitored at various intervals to assess changes in their pain levels and overall well-being. The treatment is administered as a sublingual spray, meaning it is sprayed under the tongue for absorption.

Throughout the study, participants’ pain levels will be measured using a simple scale, and other aspects such as quality of life, sleep quality, and psychological well-being will also be evaluated. The goal is to see if AP707 can provide significant relief from chronic pain and improve the quality of life for those affected by central neuropathy.

The purpose of the study is to determine if the Capsaicin patch can improve painful symptoms of CIPN more effectively than Duloxetine after a 5-week treatment period. Participants in the study will be randomly assigned to receive either the Capsaicin patch or Duloxetine. The study will last for several weeks, during which participants will receive their assigned treatment and be monitored for changes in their symptoms.

Throughout the study, participants will have regular check-ins to assess their pain levels and any changes in their quality of life. The study will also evaluate the safety of the treatments and their impact on non-painful symptoms like tingling and numbness. The goal is to find a treatment that provides significant relief from the painful symptoms associated with CIPN and improves the overall well-being of those affected by this condition.

Participants in the study will undergo two MRI scans. One scan will use the new contrast agent, gadoquatrane, and the other will use one of the approved contrast agents. The contrast agents are substances that help improve the clarity of the images produced by the MRI, making it easier for doctors to see and assess any abnormalities. The study aims to determine if gadoquatrane is as effective and safe as the other contrast agents currently in use.

The study will involve a series of MRI scans to assess the effectiveness of the contrast agents in enhancing the images. The results will help determine if gadoquatrane can be a reliable alternative to the existing contrast agents. Participants will be monitored for any side effects or adverse reactions during the study period, which will last for a short duration. The findings from this study could potentially lead to improved imaging options for patients undergoing MRI scans for various health conditions.